Oral Presentations 7 by unknown
ORAL PRESENTATIONS 7
7.1
TARGETING SMRT CO-REPRESSOR COMPLEXES AS A NOVEL 
CHEMOPREVENTION STRATEGY FOR  PROSTATE CANCER
L.M. Gommersall 4, F.L. Khanim 1, D.M. Peehl 2, A.P. Doherty 4,
N.D. James 3, M.J. Campbell 1
1 Institute of Biomedical Research, University of Birmingham, 
Birmingham, United Kingdom, 2 Department of Urology, Stanford 
University, Stanford, United States, 3 Division of Cancer Studies, 
University of Birmingham, Birmingham, United Kingdom, 4 
Department of Urology, Queen Elizabeth Hospital, Birmingham, 
United Kingdom
We hypothesized that epigenetic mechanisms silence the responsiveness of key 
antiproliferative target genes for the vitamin D receptor resulting in insensitivity. 
Supportively using quantitative real time RT-PCR (Q-RT-RCR) we found elevated 
mRNA levels of the co-repressor SMRT in 1α,25(OH)2D3-resistant prostate 
cancer cell lines. Similarly 10/15 primary tumour cultures (including 3 matched to 
normal cells from the same donors) had elevated SMRT.       
Targeted strategies towards SMRT complexes with combinations of 1α,25(OH)2D3 
and the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) resulted in 
synergistic inhibition of proliferation, and co-operative upregulation of genes 
including MAPK-APK2 and GADD45α. MRNA time course studies measured by 
Q-RT-PCR combined with protein and inhibitor studies conﬁ  rmed these patterns 
and signiﬁ  cance of regulation. Supportively primary cancer cultures with elevated 
SMRT demonstrated suppressed GADD45α induction compared to matched 
normal controls, and siRNA towards SMRT in PC-3 cells signiﬁ  cantly enhanced 
GADD45α induction.
These actions are not restricted to the VDR as multiple nuclear receptor ligands 
synergise with the clinically relevant HDAC inhibitor suberoylanilide hydroxamic 
acid (SAHA). High dose SAHA alone ( 2 µM) disrupted cytokiniesis and 
induced apoptosis, whereas doses  1 µM resulted in a G1 arrest associated with 
a rapid induction of p21(waf1/cip1) mRNA and protein. We subsequently pursued the 
combinatorial antiproliferative action of SAHA (0.5 µM) with bezoﬁ  brate (BF) 
(which targets PPARα and γ), and demonstrated synergistic antiproliferative 
actions concomitant with cell cycle arrest. Similarly siRNA towards SMRT 
resulted in enhanced upregulation of GADD45α in response to BF.  These data are 
consistent with a model of SMRT-mediated promoter-speciﬁ  c epigenetic silencing 
of multiple NR target genes and highlights a novel chemotherapy target.
7.2
FIBROBLAST GROWTH FACTOR (FGF) 17 EXPRESSION IS
UP-REGULATED HUMAN PROSTATE CANCER AND 
CORRELATES TO CLINICAL PROGNOSIS
R Heer , D Douglas , CN Robson , HY Leung 
Urology Research Group, Northern institute for cancer research, 
Newcastle upon Tyne, United Kingdom
Introduction: Over-expression of ﬁ  broblast growth factor-8 (FGF8) in
human prostate cancer is associated with clinically aggressive disease.
Among different members of the FGF family, FGF17 and FGF8 share a
high sequence homology and have similar patterns of expression during
embryogenesis.   We tested the clinical signiﬁ  cance of FGF17 expression
and its in vitro function in prostate cancer cells. 
Methods:  We studied forty resected prostate specimens, using semi-
quantitative RT-PCR, from patients with benign prostatic hyperplasia
(BPH, n=12) and prostate cancer (CaP, n=28; Gleason sum scores 3
- 10).  In addition, 85 CaP (Gleason sum scores 5 – 9) were examined
using immunohistochemistry with an optimised protocol for FGF17
immunoreactivity and ﬁ  ndings were correlated with clinical parameters.
Results:  Semi-quantative RT-PCR analysis for mRNA expression
demonstrated a 4 fold up-regulation of FGF17 expression in high grade
CaP (Gleason sum score 7 – 10) specimens when compared to BPH (p
< 0.0001). Both immunohistochemistry and RT-PCR studies revealed a
signiﬁ  cant linear correlation with increasing Gleason sum score of cancer
and FGF17 mRNA and protein expression (p<0.0001, Rho=0.99). Survival
analysis showed that men with tumours displaying high levels of FGF17
expression had a worse prognosis (p = 0.044) and was associated with the
presence of metastases (p <0.0001).  Furthermore, we demonstrated FGF8
mediated induction of FGF17 in prostate cancer cell lines (LNCaP, DU145
and PC3M). This was further validated using a neutralising antibody
speciﬁ  c to FGF8 which resulted in down-regulation of FGF17 expression.
Conclusions:  Our data support a role for FGF17 in human prostate
carcinogenesis and has revealed evidence for the control of FGF17
expression by FGF8.
7.3
PREDICTION OF SKELETAL COMPLICATIONS IN METASTATIC 
BONE DISEASE AND STRATEGIES FOR MANAGEMENT OF 
TREATMENT-INDUCED BONE LOSS 
J E Brown 
University of Shefﬁ  eld, Weston Park Hospital, Shefﬁ  eld, United 
Kingdom
The skeleton is the most frequent site of metastasis from a range of common 
cancers and bone metastasis results in skeletal complications which can be 
devastating to quality of life. At the other end of the spectrum, combination 
chemotherapy and hormone therapy may be curative, but may lead to long 
term bone loss and skeletal morbidity.  Bisphosphonates have made a major 
contribution to the management of these conditions, but there is a need 
to develop methods for prediction of risk of skeletal complications and 
assessment of response to therapy, in order to direct treatment to obtain 
optimum beneﬁ  t.  
In 121 patients with metastatic bone disease, the bone resorption marker 
N-telopeptide (NTX) was measured at monthly intervals and skeletal 
complications were recorded. There was a strong correlation between 
skeletal complications and NTX levels (r = 0.62, p<.001) and NTX was 
highly predictive for the skeletal complications experienced by a patient 
in the following 3 months.  This was the ﬁ  rst study to demonstrate such 
a relationship and was the foundation for a further larger study in which 
we used data from 3,000 patients in international, multicentre trials with 
zoledronic acid. The larger study conﬁ  rmed that bone markers are powerful 
tools in predicting impending skeletal morbidity.  Additionally, in the ﬁ  rst 
study of its kind, we demonstrated the value of bone markers in tailoring 
dosing and scheduling of a bisphosphonate to individual patients.
In a trial of 216 long term survivors from testicular cancer and lymphoma, we 
have shown (reassuringly) that there is no signiﬁ  cant effect of chemotherapy 
on bone loss compared with a control group. In a further trial in patients 
with treatment-induced osteoporosis or osteopenia, the feasibility of single 
annual doses of zoledronic acid to treat bone loss is being assessed (to date
n = 74). Initial results show that this is feasible, convenient and effective with 
sustained increases in bone mineral density ranging from 2.8% to 3.7% from 
a single drug infusion.
7.4
ACCURACY OF CT SCAN IN STAGING OF RENAL CELL 
CARCINOMA
BK Somani , A Chakravarti , MA Jones , K Kadow 
Sandwell & West Birmingham hospitals NHS Trust, Birmingham, 
United Kingdom
To evaluate the efﬁ  cacy of CT scan in the pre-operative staging of Renal
tumours.
In a retrospective cohort study of 45 patients who had radical
nephrectomy for renal tumour between 1995 – 2000, CT scan and
histopathological ﬁ  ndings were compared. We looked at the tumour
size, capsular invasion, renal vein invasion and lymph node status on
CT scan and histopathological reports.
CT scan was accurate in predicting the size of tumour in 14% of cases.
The mean variation was 1.6 cm (Range : 0.5 – 8 cm). Capsular invasion
was detected by CT scan in 45% (6 of 14) patients who had true capsular
invasion on histopathology. Renal vein invasion was not identiﬁ  ed by
CT scan in any of the 6 patients, who had histopathologically proven
invasion. Lymph Node invasion was identiﬁ  ed in 3 patients on CT
scan of which only 1 was a true invasion seen on histology. However
it failed to identify positive lymph nodes in 2 other patients who had
histologically proven lymph node metastasis.
Although CT scan is a useful tool in the diagnosis of renal masses, its
accuracy in staging renal tumours preoperatively is limited.
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PRELIMINARY EXPERIENCE USING HIGH-INTENSITY 
FOCUSED ULTRASOUND FOR THE TREATMENT OF KIDNEY 
AND LIVER TUMOURS
RO Illing 1, JE Kennedy 1, F Wu 2, GR terHaar 3, RR Phillips 1,
AS Protheroe 1, MR Middleton 1, DW Cranston 1
1 Churchill Hospital, Oxford, United Kingdom, 2 Clinical Center 
for Tumor Therapy, Chongqing University of medical Sciences, 
Chongqing, China, 3 Royal Marsden Hospital, Sutton,
United Kingdom
High-intensity focused ultrasound (HIFU) provides a potential non-invasive 
alternative to conventional therapies.  The extracorporeal ultrasound-guided 
Model-JC Tumor Therapy System (HAIFU™ Technology Company, China) 
has been used to evaluate the safety and feasibility of treating renal and liver 
tumours.  A part of each tumour was treated under general anaesthesia in a 
single session according to 3 trial protocols.  MRI after 12 days provides an 
initial assessment of response. In both the 1st and 2nd protocols, patients with 
liver tumours are treated and then imaged on day 12. Those in the 1st protocol 
are followed up with further MRI evaluation at 3 months. In the 2nd protocol the 
patients undergo partial hepatectomy enabling histological evaluation of the 
ablated region. The 3rd protocol evaluates the treatment of large kidney tumours 
prior to elective nephrectomy.  16 liver and 5 kidney patients have been treated 
to date.  Of the 16 liver patients, 10 have been enrolled into the ﬁ  rst protocol, 
one non-evaluable. One patient died prior to post-treatment MRI (unrelated to 
treatment). 7 of the remaining 8 patients have shown clear evidence of tumour 
ablation on post-treatment MRI. 6 liver patients and 5 kidney patients have 
gone on to surgery. Post-HIFU MRI revealed volumes of ablation in all 6 liver 
patients which correlated with the histological ﬁ  ndings. Post-treatment MRI 
evaluation of the kidney tumours showed evidence of ablation in 2 of the 5 
cases, however there was only clear histological correlation in one of these. 
Mild transient pain was reported by 55% of patients, and more severe pain in 
one case. Superﬁ  cial skin burns were seen in 7 patients (35% of cases).  Our 
early experience suggests that HIFU treatment of liver and kidney tumours is 
safe and has few complications or side effects. MRI evidence of ablation has 
been apparent in 80% of those patients treated (liver 93%, kidney 40%), and 
histological changes consistent with ablation have been recorded in 64% of 
patients (liver 100%, kidney 20%).
7.6
INFLIXIMAB: A PHASE II TRIAL OF THE TUMOUR NECROSIS 
FACTOR (TNFα) MONOCLONAL ANTIBODY IN PATIENTS WITH 
ADVANCED RENAL CELL CANCER (RCC)
NR Maisey , K Hall , C Lee , E Timotheadou , R Ahern , T Eisen ,
M Gore 
Royal Marsden Hospital, London, United Kingdom
Background: Several small peptides are over-expressed in RCC including
TNFα. Trials of thalidomide have shown promising results in advanced
RCC, possibly due to the down-regulation of some of these peptides
including TNFα. Inﬂ  iximab is a chimeric human / mouse monoclonal
antibody against TNFα. We have performed a phase II study of this in pts
with RCC.
Methods:This was an open, single arm, phase II study using a 2 stage
Gehan design. Eligibility criteria: metastatic RCC progressing after
immunotherapy (IFα +/or IL2), performance status (PS) 0-2, life
expectancy >12 weeks. Inﬂ  iximab (5mg/kg) was administered on weeks 0,
2, 6, 14, 22, 30. Treatment could continue until progressive disease (PD).
Response was assessed before each dose from week 6.
Results: 19 patients are evaluable for toxicity and 18 for response. Median
follow-up: 125 days (range 25-318). Median age: 53 (35-76). First-line
immunotherapy included: IFα (n=12); IFα/IL2/5-Fluorouracil (n=7).
Additional lines of treatment prior to study entry were given to 8 patients
including IF?/IL2/5-Fluorouracil, GW57016, Vinﬂ  unine, B-Raf inhibitor,
gemcitabine/capecitabine, medroxyprogesterone acetate. Patients received
the following number of doses: 1 (n=19); 2 (n=18); 3 (n=12); 4 (n=5);
5 (n=3); 6 (n=1). 2 patients achieved partial response (PR) at 14 and 30
weeks. 1 late response (15 weeks) was observed following initial PD at
6 weeks. 4 patients have ongoing disease control (PR + stable disease) at
1,2,3,9 months. Probability of survival at 9 months is 47% (95% CI 13-75).
Median progression free survival is 56 days (95% CI 31-81). Other than 1
episode of grade 3 hypersensitivity there were no signiﬁ  cant toxicities.
Conclusions:This study shows that inﬂ  iximab is non-toxic and active in
RCC. 2 patients achieved PR and 1 patient had a late response. Further
studies are warranted to investigate the potential role of inﬂ  iximab in the
management of RCC.
7.7
A RANDOMISED TRIAL OF CARBOPLATIN VERSUS 
RADIOTHERAPY FOR STAGE I SEMINOMA OF THE TESTIS, 
FOLLOWING ORCHIDECTOMY: MRC TE19/EORTC 30982
RTD Oliver 1, M Mason 2, H Von der Maase 3, SP Stenning 4, SJ Kirk 4, 
GJS Rustin 5, GM Mead 6, R de Wit 7
1 St Bartholomew’s Hospital, London, United Kingdom, 2 Velindre 
Hospital, Cardiff, United Kingdom, 3 Aarhus University Hospital, 
Aarhus, Denmark, 4 MRC Clinical Trials Unit, London, United 
Kingdom, 5 Mt Vernon Hospital, Northwood, United Kingdom,
6 Southampton General Hospital, Southampton, United Kingdom,
7 Erasmus Medical Centre, Rotterdam, Netherlands
Background: Prompted by evidence that radiotherapy (R) for stage I seminoma 
increases late malignant and cardio-vascular events, MRC trials have investigated 
reduced radiation volume (TE10) and reduced dose(TE18) without loss of 
effectiveness.  The latest trial compares radiation and 1 course of carboplatin (C) 
and the initial results of this study are presented  
Methods: Randomisation was between R and 1 course of C AUCx7.  An optional 
randomisation was allowed between 20 Gy/10f and 30 Gy/15f as in TE18. The trial 
was powered to exclude absolute differences in the 2 year relapse rates of >3%.
Results: From June 96 to March 01 1447 patients (pts) were randomised (ratio 3:
5) between C and R. Of pts randomised to R 13% had dogleg ﬁ  eld and 87% PA 
strip. Median follow up (FU) is now 3 years and over 90% of patients have at least 
2 years FU. Relapse-free survival rates for R vs C (95%CI) are 97.2% (95.9, 98.1) 
v 98.1% (96.6, 98.9) at 2 years and 96.6% (95.2, 97.6) v 95.4% (93.3, 96.9) at 3 
years; HR 1.39 (90% CI: 0.92, 2.11) p=0.195; the 90% CI excludes an increase 
in relapse rates in the C arm of more than 3% at 2 years and of more than 4% at 
3 years. Pattern of relapse varied, sites being the PA nodes only in 70% (C) v 7% 
(R), and pelvis relapse in 4% (C) vs 28%(R). Second germ cell tumours (GCTs) 
have been reported in 1 pt allocated C and 7 allocated R, non-GCTs 2 C vs 4 
R. No disease or treatment related deaths have been reported after C and only 
1 after R; non-cancer deaths 1 (C) vs 2 (R). There was no difference in gonadal 
function(FSH, LH & Testosterone) between arms at 1 & 2 years
Conclusions: With a median FU of 3 years, an absolute increase in relapse rate 
in the C arm of more than 3% at 2 years can be excluded reliably, early data on 
new primary cancers favour the C group and to date there have been no disease 
or treatment related deaths. Further FU is needed to conﬁ  rm that these results are 
maintained beyond 3 years.
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